Organ donation and transplantation is a successful therapy that provides cure to some categories of patients suffering from serious organ failures(kidney,heart,liver,lung,pancreas,and bowel).As it is well known,the number of organ donors is still insufficient in all European MS,but another value that should be also considered is the number of organs that are used per donor.Since not all tx programs are running in all EU countries yet,and it is more difficult to find the correct compatibility for some patient categories,it may happen that some organs are not allocated at national level,mainly because there is no suitable recipient on the national WL.These organs although suitable are unfortunately wasted although they could be used in another country.First outcomes of COORENORproject show that the present number of exchanges could grow substantially.The main aim of this action is therefore to better practice of exchange of organs with the end objective of increasing bilateral agreements,and an overallapproach that includes raising awareness and preventing wrong communication attitude.


HCV infects and affects a population in the EU who do not access care. The arrival of new curative HCV drugs are a great opportunity for those resourced to attend services and adhere to treatment, but this adherent population is the minority in the EU. If we aim to cure HCV in all risk groups we must take the treatment to the patient and vice-versa. The activities will support the development of national hepatitis strategies, screening and treatment guidelines, taking into account available treatment options. It will help to bridge primary, secondary care, and outreach in the community to facilitate access to and uptake of testing and treatment services particularly among key risk groups including drug users and homeless. It will also assess the potentially considerable economic impact of available treatment and testing strategies on health systems, which are under the responsibility of the EU Member States, with a view to inform decisions on balancing access to medicines with the financial sustainability of health systems. The HepCare project will contain six different components.HepCheck will aim at intensifying screening in the communityHepLink will link primary and secondary care HepEd will educate and up-skill healthcare professionals in the treatment of Hepatitis CHepFriend will provide a peer advocate support programme for patients to help treatment outcomesHepCost will assess the economic impact of the projectThe coordinator will have overall responsibility for disseminating the project impact and liaising with decision makers.The project will take place in 4 member states: Ireland, the UK, Spain and Romania.The HepCare Project will build on work undertaken by the European Commission, the European Centre for Disease Control and Prevention, and the European Monitoring Centre for Drugs and Drug Addiction with the aim of reducing morbidity and mortality related to hepatitis C and reducing the socioeconomic impact of hepatitis in the EU/EEA.


Rare diseases (RD) have been identified as one of the paradigmatic fields in which actions conducted at the European level constitute the adequate response to their specific problems: poor recognition leading to diagnostic delay and inappropriate management including adapted social services, poor health outcomes, social burden, limited knowledge on natural history and pathophysiology leading to an insufficient development of new therapies. The low prevalence and the specificity of RD make that a global, multi-stakeholder approach, intended to gather specific expertise and to build shared strategies is necessary to address these issues.
The general objectives of RD-Action are to:
▪ Support the further development and sustainability of the Orphanet database, the biggest global repository of information on RD
▪ Contribute to solutions to ensure an appropriate codification of RD in health information systems
▪ Continue implementation of the priorities identified in Council Recommendation 2009/C151/02 and the Commission Communication (COM 2008 679) on RD, with a view to ensuring the sustainability of the recommended priority actions and to support the work of the Commission Expert Group on Rare Diseases (CEGRD).
This JA will expand and consolidate the achievements of the former JAs on RD supported by the European Commission: the Orphanet JA and the EUCERD JA. More precisely, this proposal has the ambition to help member states to implement the recommended measures adopted or to be adopted by the CEGRD and to produce the data necessary for countries to do so. Interactions between the production of data at the Orphanet database level and the implementation of policy priorities including codification will be strengthened during this JA.RD-Action large geographical coverage is key to success as it will promote the transfer of European recommendations into national policies and the collection of information and concerns from MS to the CEGRD, thus to the European Commission.



The aim is to develop competency-based standards and an accreditation system for health promotion practice, education and training, to boost the capacity of the workforce to deliver public health improvement in Europe.

